Download Files:
PCSK9-IN-10
$120 – $980
Products Details
Product Description
– PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia[1].
Web ID
– HY-152221
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Molecular Formula
– C18H23N5O4
References
– [1]Qiao MQ, et al. Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis. Eur J Med Chem. 2022 Dec 26;247:115047.
CAS Number
– 368434-98-4
Molecular Weight
– 373.41
Compound Purity
– 98.95
SMILES
– O=C(N1C)N(C)C2=C(N(CC3=CC=CC(OC)=C3)C(NCCOC)=N2)C1=O
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– Ser/Thr Protease
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
